| Name | Title | Contact Details |
|---|
SMART CHEMISTRY WITH CHARACTER. The CHT Group is a medium-sized global player for sustainable specialty chemicals. After the foundation of CHT R. Beitlich GmbH in 1953 in Tübingen, the company has developed to a worldwide operating group with focus on innovative chemicals as function generators, auxiliaries and additives for industrial processes. The products optimise production processes in many industries and have an influence on the functionality, appearance and quality of the end-products on the consumer market. Then as now, the head office and the centres of competence of the business fields are located at the headquarters of the company CHT Germany GmbH in Tübingen (Ger). The range of dyes is developed, produced and commercialised by the Swiss subsidiary company CHT Switzerland AG (former BEZEMA AG) in Montlingen. With worldwide approx. 2,500 staff members in 28 companies and additional sales agencies the company group provides its products and services in more than 120 countries – on all continents. In strategy and organisation the group is focused on a value-oriented and sustainable corporate policy. Four business fields have the operative responsibility for the CHT business development: Textile, Textile Care, Construction Chemistry and General Industries. Production and finishing of textiles: Process auxiliaries, function generators and additives for pretreatment, dyeing, textile printing, flock, finishing, coating, jeans & garment, fiber production and textiles dyes. Washing Solutions: Detergents and auxiliaries for industrial laundries and for the feather and down industry. Construction: Additives, binders and special components for mineral systems and paints & coatings. General Industries: Silicones for Material Solutions, Consumer Care Solutions, Paper Solutions, Agricultural Solutions, Leather Solutions and Mining Solutions. In addition the CHT Group successfully established itself in PET recycling.
"Love of invention will never end." - Carl Benz Learn more about us as we continue to pioneer the future of driving excellence. Data privacy: mb4.me/provider_privacy Imprint: Mercedes-Benz AG Mercedesstraße 120 D-70372 Stuttgart Deutschland Tel.: +49 7 11 17-0 E-Mail: dialog.mb@mercedes-benz.com Vertreten durch den Vorstand: Ola Källenius (Vorsitzender), Jörg Burzer, Renata Jungo Brüngger, Sabine Kohleisen, Harald Wilhelm, Markus Schäfer, Britta Seeger Vorsitzender des Aufsichtsrats: Martin Brudermüller Handelsregister beim Amtsgericht Stuttgart, Nr. HRB 762873 Umsatzsteueridentifikationsnummer: DE321281763
Turner Surety and Insurance Brokerage, Inc. (TSIB) is a full-service brokerage that specializes in controlled insurance programs and traditional property and casualty placements. The company focuses on construction risk management, serving owners, developers, and contractors. TSIB has extensive experience in managing construction risks, particularly through Controlled Insurance Programs (CIPs) and Owner-Controlled Insurance Programs (OCIPs), ensuring effective risk management and safety controls. TSIB has worked on over 450 healthcare projects, totaling more than $20 billion in construction volume. They offer customized insurance programs and reinsurance solutions, supporting the Managing General Agent (MGA) community. Their services also include consulting for professional services, surety programs, and various health-related benefits. TSIBs expertise in Wrap-Up programs helps manage construction projects comprehensively, from orientation to financial auditing.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.